A Comparison of Glypican-3 with Alpha-fetoprotein As a Serum Marker for Hepatocellular Carcinoma: a Meta-analysis

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2013 Jun 8

PMID 23743582

Citations 26

Authors

Cheng Xu

Zhehui Yan

Liang Zhou

Yuming Wang

Affiliations

Soon will be listed here.

Abstract

Backgrounds: Glypican-3(GPC3) has been reported as one of the most promising serum markers for hepatocellular carcinoma (HCC), while several studies have conflicting results for the diagnostic accuracy between GPC3 and alpha-fetoprotein (AFP).

Methods: Studies that explored the diagnostic value of GPC3 and AFP in HCC were searched in MEDLINE, EMBASE, PUBMED, the Cochrane Library and Chinese biomedical literature database (CBM). Sensitivity, specificity and other measures about the accuracy of serum GPC3 and AFP in the diagnosis of HCC were pooled using random effects models. Summary receiver operating characteristic curve (sROC) analysis was used to summarize the overall test performance.

Results: Ten studies were included in our meta-analysis. The pooled sensitivity for AFP and GPC3 is 51.9% (95% confidence interval (CI) 0.47-0.56) and 59.2% (95% CI 0.55-0.63), respectively, while the pooled specificity for AFP and GPC3 is 94% (95% CI 92.1-95.6%) and 84.8% (95% CI 82-87.3%), respectively. The pooled diagnostic odds ratio (DOR) for AFP and GPC3 were 23.4 (95% CI 10.3-53.2) and 17.99 (95% CI 5.4-60.4), respectively. Area under sROC for both AFP and GPC3 is 0.81 (95% CI 0.77-0.84).

Conclusions: GPC3 is comparable to AFP as a serum marker for the diagnosis of HCC, combination of AFP and GPC3 can elevate the sensitivity of diagnosis.

Citing Articles

A transformer-based deep learning survival prediction model and an explainable XGBoost anti-PD-1/PD-L1 outcome prediction model based on the cGAS-STING-centered pathways in hepatocellular carcinoma.

Wang R, Liu Q, You W, Wang H, Chen Y Brief Bioinform. 2025; 26(1).

PMID: 39749665 PMC: 11695900. DOI: 10.1093/bib/bbae686.

Differences in Prediagnostic Serum Metabolomic and Lipidomic Profiles Between Cirrhosis Patients with and without Incident Hepatocellular Carcinoma.

Powell H, Coarfa C, Ruiz-Echartea E, Grimm S, Najjar O, Yu B J Hepatocell Carcinoma. 2024; 11:1699-1712.

PMID: 39263690 PMC: 11389719. DOI: 10.2147/JHC.S474010.

Biomarker in Hepatocellular Carcinoma.

Basthi Mohan P, Lochan R, Shetty S Indian J Surg Oncol. 2024; 15(Suppl 2):261-268.

PMID: 38817995 PMC: 11133295. DOI: 10.1007/s13193-023-01858-x.

Serum tRF-33-RZYQHQ9M739P0J as a novel biomarker for auxiliary diagnosis and disease course monitoring of hepatocellular carcinoma.

Li X, Li Y, Yuan J, Zhang W, Xu T, Jing R Heliyon. 2024; 10(9):e30084.

PMID: 38707447 PMC: 11068615. DOI: 10.1016/j.heliyon.2024.e30084.

Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.

Fares S, Wehrle C, Hong H, Sun K, Jiao C, Zhang M Cancers (Basel). 2024; 16(8).

PMID: 38672535 PMC: 11047909. DOI: 10.3390/cancers16081453.

References

Cleophas T, Zwinderman A . Meta-analyses of diagnostic studies. Clin Chem Lab Med. 2009; 47(11):1351-4. DOI: 10.1515/CCLM.2009.317. View

Capurro M, Wanless I, Sherman M, Deboer G, Shi W, Miyoshi E . Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125(1):89-97. DOI: 10.1016/s0016-5085(03)00689-9. View

de Sousa M, Ribeiro A . Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial. Arq Bras Cardiol. 2009; 92(3):229-38, 235-45. DOI: 10.1590/s0066-782x2009000300013. View

Capurro M, Filmus J . Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res. 2005; 65(1):372. View

Dinnes J, Deeks J, Kirby J, Roderick P . A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess. 2005; 9(12):1-113, iii. DOI: 10.3310/hta9120. View

Zhu Z, Friess H, Wang L, Zimmermann A, Lander A, Korc M . Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001; 48(4):558-64. PMC: 1728256. DOI: 10.1136/gut.48.4.558. View

Filmus J, Selleck S . Glypicans: proteoglycans with a surprise. J Clin Invest. 2001; 108(4):497-501. PMC: 209407. DOI: 10.1172/JCI13712. View

Filmus J, Capurro M . Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2005; 8(4):207-12. DOI: 10.1007/BF03260065. View

Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno G . Hepatocellualar carcinoma serum markers. Semin Oncol. 2012; 39(4):410-33. DOI: 10.1053/j.seminoncol.2012.05.001. View

10.

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A . Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006; 6:31. PMC: 1552081. DOI: 10.1186/1471-2288-6-31. View

11.

Nobuoka D, Kato Y, Gotohda N, Takahashi S, Nakagohri T, Konishi M . Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep. 2010; 24(2):521-8. DOI: 10.3892/or_00000888. View

12.

Liu H, Li P, Zhai Y, Qu C, Zhang L, Tan Y . Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010; 16(35):4410-5. PMC: 2941063. DOI: 10.3748/wjg.v16.i35.4410. View

13.

Yao M, Yao D, Bian Y, Zhang C, Qiu L, Wu W . Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011; 10(3):289-94. DOI: 10.1016/s1499-3872(11)60048-9. View

14.

Honest H, Khan K . Reporting of measures of accuracy in systematic reviews of diagnostic literature. BMC Health Serv Res. 2002; 2:4. PMC: 100326. DOI: 10.1186/1472-6963-2-4. View

15.

Bian Y, Yao D, Zhang C, Li S, Wu W, Dong Z . [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(4):260-5. DOI: 10.3760/cma.j.issn.1007-3418.2011.04.008. View

16.

Moriguchi H, Sato C . The values and limitations of glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic viewpoints. Gastroenterology. 2004; 127(2):679-80. DOI: 10.1053/j.gastro.2004.03.082. View

17.

Capurro M, Xiang Y, Lobe C, Filmus J . Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005; 65(14):6245-54. DOI: 10.1158/0008-5472.CAN-04-4244. View

18.

Komori H, Beppu T, Baba H, Nakatsura T, Nishimura Y . [Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma]. Nihon Rinsho. 2010; 68 Suppl 7:833-6. View

19.

Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C . AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008; 8:200. PMC: 2488355. DOI: 10.1186/1471-2407-8-200. View

20.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View